B
altimore’s Vita Therapeutics announced the completion of a $31 million series B funding round on Wednesday, propelling the cell therapy company toward a clinical trial and the development of new treatments for rare diseases.
Image: Vita Therapeutics, led by CEO Douglas Falk, recently completed a $31 million series B funding round. – Douglas Falk
{iframe}https://www.bizjournals.com/baltimore/inno/stories/fundings/2022/10/12/vita-therapeutics-funding-round-genetic-diseases.html?utm_campaign=manual&utm_medium=trueAnthem&utm_source=linkedin{/iframe}